An excerpt regarding the missing therapeutics in the fight against Covid while they promote sale of vaccines -- 1 dose, 2 dose, 3 dose, +++?
Monday, October 18, 2021 3:30 PM EDT
Summary
It seems even more self-evident than before that therapeutics are the missing link in the White House’s COVID-19 strategy. With the rising number of breakthrough infections the vaccine is clearly not stopping the spread as originally planned. Policies that give preference to vaccine card holders are equally as dangerous by giving people a false sense of security. For example, some restaurants in California require proof of a current vaccination to get into a restaurant while displacing a patron with a current negative COVID-19 test. The public is seeing the various cracks in the vaccination-only strategy and that is translating into lowered expectations for the vaccine makers. Vaccines with quickly waning effectiveness cannot protect against the community spread. The lack of adequate testing surveillance is partially responsible for this latest delta wave as many thought in early summer the pandemic was ending. The epic blunder of not utilizing the cPass as a screening test to determine booster eligibility has created a state of vaccine polarization that cannot be undone.
Mutations are likely to continue and the next one that finds its way around the current vaccines would leave the world completely unprotected. This cycle has to stop, and only oral antivirals that are easy to dispense, easy to mass-produce, and safe to take can put an end to the pandemic and the variants that come with it. Tollovir made by TOMDF is the most promising oral antiviral because it cares not about vaccination status, cares not about underlying conditions, cares not about what stage of disease you are in, and just focuses on ridding the virus as quickly as possible, reducing infectiousness, and making the person feel better. While molnupiravir might work on a very narrow subset of patients its safety profile is questionable and it has nowhere near the safety profile of Tollovir.
At some point stopping the spread has to be a priority. Many that get the disease can end up with Long Haulers. Vaccines are unable to stop this which is why disease prevention via oral antivirals is so essential. Instead of letting science lead to answers and solutions, the FDA has chosen to rely on big pharma even though little pharma seems to have the perfect package. How many more people have to die for a p-value? People are demanding an oral antiviral now and the rise in TOMDF seems to be reflecting those attitudes because TOMDF has an oral antiviral with extremely strong mortality data and an interim readout possible before Merck's meeting with the FDA about molnupiravir. However, what makes them standout is their ability to produce a nutraceutical equivalent that can be purchased today at www.mytollovid.com or Amazon.com.Virally spreading the message of this nutraceutical may be the key to actually beating the virus instead of living with it. Although some have written off the hope of finding a cure for this plague the only thing that we should be writing off is the hope of big pharma finding that solution. There are clear indications that smaller players have viable solutions that save lives and have better risk profiles than the big pharma whose focus is on recurring revenue streams instead of healing people.